Uncategorized

Ollin parlays Vabysmo beat into $330M raise to test eye disease drug in Phase 3

Published

on

With positive feedback on a Phase 3 trial design, Ollin Biosciences has collected a $330 million series B to advance its VEGF/Ang2 antibody, which bested Genentech’s therapy in a head-to-head study.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version